Dataset: Transcription profiling by array of human acute myeloid leukemia patients

High VEGFC mRNA expression of AML blasts is related to increased in vitro and in vivo drug resistance. The prognostic significance of...

Registered by ArrayExpress Uploader

View Dataset

High VEGFC mRNA expression of AML blasts is related to increased in vitro and in vivo drug resistance. The prognostic significance of VEGFC on long-term outcome and its associated gene expression profiles remain to be defined. We studied the effect of VEGFC on treatment outcome and investigated gene expression profiles associated with VEGFC using microarray data of 525 adult and 100 pediatric AML patients. High VEGFC expression appeared strongly associated with reduced complete remission rate, reduced overall and event-free survival (OS and EFS) in adult AML. Multivariable analysis established high VEGFC as prognostic indicator independent of cytogenetic risk, FLT3-ITD, NPM1, CEBPA, age and WBC. Also in pediatric AML high VEGFC was related to reduced OS. A unique series of differentially expressed genes was identified that distinguished AML with high VEGFC from AML with low VEGFC, i.e., 331 upregulated genes (representative of proliferation, VEGF-receptor activity, signal transduction) and 44 downregulated genes (e.g. related to apoptosis) consistent with a role in enhanced chemoresistance. In conclusion, high VEGFC predicts adverse long-term prognosis and provides prognostic information in addition to well-known prognostic factors. 98 bone marrow and peripheral blood samples were collected at diagnosis and frozen. They were later thawed and hybridized to Affymetrix U133 Plus 2.0 arrays.

Species:: human
Samples:: 98
Source:: E-GEOD-22056
PubMed:: 20522712
Updated:: Dec.12, 2014
Registered:: Sep.15, 2014

Factors: (via ArrayExpress)

Sample	PATIENT ID	COHORT	KARYOTYPE	GENOTYPE
GSM44592	2	Validation	MLL-rearrangement	wild type
GSM445922	3	Discovery	t(8;21)	wild type
GSM445923	4	Discovery	t(15;17)	FLT3-ITD mutant
GSM445925	6	Validation	remaining cytogenetics	wild type
GSM445926	7	Validation	MLL-rearrangement	N/K-RAS mutant
GSM445927	8	Discovery	unknown cytogenetics	N/K-RAS mutant; FLT3-ITD mutant
GSM445928	9	Validation	remaining cytogenetics	FLT3-ITD mutant
GSM445929	10	Discovery	unknown cytogenetics	wild type
GSM445930	11	Discovery	remaining cytogenetics	NPM1 mutant
GSM44593	12	Discovery	MLL-rearrangement	wild type
GSM445932	13	Validation	MLL-rearrangement	PTPN11 mutant
GSM445933	14	Validation	unknown cytogenetics	NPM1 mutant; FLT3 mutant
GSM445934	15	Validation	unknown cytogenetics	CEBPA mutant
GSM445935	16	Validation	t(8;21)	C-KIT mutant
GSM445936	17	Validation	MLL-rearrangement	N/K-RAS mutant
GSM445937	18	Discovery	CN-AML	NPM1 mutant; FLT3-ITD mutant
GSM445938	19	Discovery	t(8;21)	N/K-RAS mutant
GSM445939	20	Discovery	inv(16)	C-KIT mutant
GSM445940	21	Discovery	inv(16)	C-KIT mutant
GSM44594	22	Validation	remaining cytogenetics	N/K-RAS mutant
GSM445942	23	Discovery	MLL-rearrangement	wild type
GSM445943	24	Discovery	t(8;21)	wild type
GSM445944	25	Discovery	CN-AML	N/K-RAS mutant; NPM1 mutant
GSM445945	26	Discovery	remaining cytogenetics	CEBPA mutant
GSM445946	27	Discovery	MLL-rearrangement	wild type
GSM445947	28	Discovery	MLL-rearrangement	N/K-RAS mutant
GSM445948	29	Validation	remaining cytogenetics	wild type
GSM445950	31	Validation	t(8;21)	C-KIT mutant
GSM44595	32	Discovery	t(7;12)	wild type
GSM445952	33	Validation	inv(16)	wild type
GSM445953	34	Discovery	remaining cytogenetics	wild type
GSM445954	35	Discovery	remaining cytogenetics	N/K-RAS mutant
GSM445959	40	Validation	t(8;21)	FLT3-ITD mutant
GSM445963	44	Validation	MLL-rearrangement	wild type
GSM445964	45	Discovery	t(8;21)	C-KIT mutant
GSM445965	46	Discovery	inv(16)	C-KIT mutant
GSM445966	47	Validation	inv(16)	N/K-RAS mutant
GSM445967	48	Validation	MLL-rearrangement	N/K-RAS mutant
GSM445968	49	Discovery	MLL-rearrangement	wild type
GSM445969	50	Validation	CN-AML	NPM1 mutant; FLT3-ITD mutant
GSM445970	51	Validation	t(8;21)	C-KIT mutant
GSM44597	52	Discovery	remaining cytogenetics	wild type
GSM445972	53	Discovery	t(8;21)	wild type
GSM445973	54	Validation	remaining cytogenetics	CEBPA mutant
GSM445974	55	Discovery	remaining cytogenetics	FLT3-ITD mutant
GSM445975	56	Discovery	remaining cytogenetics	FLT3-ITD mutant
GSM445976	57	Validation	CN-AML	MLL-PTD mutant
GSM445977	58	Discovery	MLL-rearrangement	wild type
GSM445978	59	Discovery	MLL-rearrangement	FLT3-ITD mutant
GSM445979	60	Discovery	MLL-rearrangement	wild type
GSM445980	61	Discovery	MLL-rearrangement	wild type
GSM445985	66	Discovery	remaining cytogenetics	MLL-PTD mutant; N/K-RAS mutant
GSM44604	122	Discovery	remaining cytogenetics	wild type
GSM446042	123	Validation	remaining cytogenetics	wild type
GSM446043	124	Validation	MLL-rearrangement	wild type
GSM446044	125	Discovery	remaining cytogenetics	wild type
GSM446046	127	Validation	CN-AML	FLT3-ITD mutant
GSM446047	128	Validation	inv(16)	C-KIT mutant
GSM446048	129	Discovery	MLL-rearrangement	wild type
GSM446049	130	Discovery	CN-AML	N/K-RAS mutant; NPM1 mutant
GSM446050	131	Discovery	CN-AML	N/K-RAS mutant; FLT3-ITD mutant
GSM44605	132	Discovery	t(8;21)	N/K-RAS mutant
GSM446052	133	Discovery	CN-AML	FLT3-ITD mutant
GSM446053	134	Discovery	remaining cytogenetics	wild type
GSM446054	135	Discovery	t(8;21)	wild type
GSM446055	136	Discovery	t(8;21)	wild type
GSM446056	137	Discovery	inv(16)	wild type
GSM446057	138	Validation	t(8;21)	wild type
GSM446058	139	Discovery	t(15;17)	FLT3-ITD mutant
GSM446059	140	Discovery	t(15;17)	wild type
GSM446060	141	Discovery	MLL-rearrangement	wild type
GSM44606	142	Discovery	remaining cytogenetics	wild type
GSM446062	143	Discovery	MLL-rearrangement	wild type
GSM446063	144	Discovery	CN-AML	CEBPA mutant
GSM446064	145	Discovery	MLL-rearrangement	N/K-RAS mutant
GSM446065	146	Validation	CN-AML	FLT3-ITD mutant
GSM446066	147	Discovery	t(8;21)	wild type
GSM446067	148	Discovery	t(8;21)	FLT3-ITD mutant
GSM446068	149	Discovery	CN-AML	MLL-PTD mutant; FLT3-ITD mutant
GSM446070	151	Discovery	remaining cytogenetics	wild type
GSM44607	152	Discovery	remaining cytogenetics	wild type
GSM446072	153	Discovery	CN-AML	wild type
GSM446073	154	Discovery	CN-AML	FLT3-ITD mutant
GSM446074	155	Validation	unknown cytogenetics	CEBPA mutant
GSM446076	157	Discovery	remaining cytogenetics	wild type
GSM446077	158	Discovery	remaining cytogenetics	wild type
GSM446078	159	Discovery	remaining cytogenetics	PTPN11 mutant
GSM446079	160	Discovery	MLL-rearrangement	wild type
GSM446080	161	Discovery	remaining cytogenetics	N/K-RAS mutant
GSM44608	162	Discovery	MLL-rearrangement	N/K-RAS mutant
GSM446082	163	Discovery	unknown cytogenetics	wild type
GSM446083	164	Discovery	remaining cytogenetics	CEBPA mutant; FLT3-ITD mutant
GSM446084	165	Validation	unknown cytogenetics	CEBPA mutant
GSM446085	166	Discovery	MLL-rearrangement	C-KIT mutant
GSM446086	167	Discovery	remaining cytogenetics	wild type
GSM446087	168	Discovery	unknown cytogenetics	PTPN11 mutant
GSM446088	169	Discovery	inv(16)	C-KIT mutant
GSM446089	170	Discovery	remaining cytogenetics	wild type